IBDEI024 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,441,1,3,0)
 ;;=3^Mix cellular class Hdgkn lymph, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,441,1,4,0)
 ;;=4^C81.29
 ;;^UTILITY(U,$J,358.3,441,2)
 ;;=^5001420
 ;;^UTILITY(U,$J,358.3,442,0)
 ;;=C81.30^^2^21^41
 ;;^UTILITY(U,$J,358.3,442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,442,1,3,0)
 ;;=3^Lymphocyte depleted classical Hodgkin lymphoma, unsp site
 ;;^UTILITY(U,$J,358.3,442,1,4,0)
 ;;=4^C81.30
 ;;^UTILITY(U,$J,358.3,442,2)
 ;;=^5001421
 ;;^UTILITY(U,$J,358.3,443,0)
 ;;=C81.39^^2^21^40
 ;;^UTILITY(U,$J,358.3,443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,443,1,3,0)
 ;;=3^Lymphocy deplet class Hdgkn lymph, extrnod & solid org site
 ;;^UTILITY(U,$J,358.3,443,1,4,0)
 ;;=4^C81.39
 ;;^UTILITY(U,$J,358.3,443,2)
 ;;=^5001430
 ;;^UTILITY(U,$J,358.3,444,0)
 ;;=C81.40^^2^21^42
 ;;^UTILITY(U,$J,358.3,444,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,444,1,3,0)
 ;;=3^Lymphocyte-rich classical Hodgkin lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,444,1,4,0)
 ;;=4^C81.40
 ;;^UTILITY(U,$J,358.3,444,2)
 ;;=^5001431
 ;;^UTILITY(U,$J,358.3,445,0)
 ;;=C81.49^^2^21^37
 ;;^UTILITY(U,$J,358.3,445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,445,1,3,0)
 ;;=3^Lymp-rich class Hodgkin lymph, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,445,1,4,0)
 ;;=4^C81.49
 ;;^UTILITY(U,$J,358.3,445,2)
 ;;=^5001440
 ;;^UTILITY(U,$J,358.3,446,0)
 ;;=C81.99^^2^21^35
 ;;^UTILITY(U,$J,358.3,446,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,446,1,3,0)
 ;;=3^Hodgkin lymphoma, unsp, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,446,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,446,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,447,0)
 ;;=C81.90^^2^21^36
 ;;^UTILITY(U,$J,358.3,447,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,447,1,3,0)
 ;;=3^Hodgkin lymphoma, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,447,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,447,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,448,0)
 ;;=C82.69^^2^21^17
 ;;^UTILITY(U,$J,358.3,448,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,448,1,3,0)
 ;;=3^Cutan folicl center lymphoma, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,448,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,448,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,449,0)
 ;;=C82.60^^2^21^18
 ;;^UTILITY(U,$J,358.3,449,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,449,1,3,0)
 ;;=3^Cutaneous follicle center lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,449,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,449,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,450,0)
 ;;=C82.49^^2^21^22
 ;;^UTILITY(U,$J,358.3,450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,450,1,3,0)
 ;;=3^Foliclar lymphoma grade IIIb, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,450,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,450,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,451,0)
 ;;=C82.40^^2^21^29
 ;;^UTILITY(U,$J,358.3,451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,451,1,3,0)
 ;;=3^Follicular lymphoma grade IIIb, unspecified site
 ;;^UTILITY(U,$J,358.3,451,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,451,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,452,0)
 ;;=C82.19^^2^21^25
 ;;^UTILITY(U,$J,358.3,452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,452,1,3,0)
 ;;=3^Follicular lymphoma grade II, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,452,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,452,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,453,0)
 ;;=C82.39^^2^21^21
 ;;^UTILITY(U,$J,358.3,453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,453,1,3,0)
 ;;=3^Foliclar lymphoma grade IIIa, extrnod and solid organ sites
 ;;
 ;;$END ROU IBDEI024
